Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026. Open the filing →
- Filed
- May 11, 2026, 7:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215702
FAQ
- What is Dyne Therapeutics, Inc.'s D&A?
- Dyne Therapeutics, Inc. (DYN) reported D&A of $550K in Q1 2026.
- How has Dyne Therapeutics, Inc.'s D&A changed year-over-year?
- Dyne Therapeutics, Inc.'s D&A increased by 9.6% year-over-year, from $502K to $550K.
- What is the long-term trend for Dyne Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Dyne Therapeutics, Inc.'s D&A has grown at a 17.0% compound annual growth rate (CAGR), from $1.08M to $2.02M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Dyne Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude